– USA, CA – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today announced that former Gilead Sciences executive Gregg Alton joined its Board of Directors. Mr. Alton has also been appointed as Chair of the Corporate Governance and Nominating Committee of the Board of Directors.
“I am excited to welcome Gregg to our Board,” said Dr Joseph Belanoff, CEO. “His twenty years of experience and broad portfolio of responsibilities at Gilead will be invaluable as our commercial operations mature and we advance our proprietary selective cortisol modulators in a wide range of serious disorders. Gregg has devoted his career to helping patients and physicians understand their treatment options and obtain access to life-saving medications.”
About Gregg Alton
Mr. Alton served as Gilead’s interim CEO from January 2019 until March 2019. Before that, he was Gilead’s Chief Patient Officer, responsible for Gilead’s government affairs, public affairs, patient outreach and engagement initiatives, as well as efforts to facilitate access to its medicines around the world. Mr. Alton also oversaw Gilead’s corporate and medical affairs functions, its digital patient solutions and patient-centered outcomes groups, and commercial operations in certain countries. He had previously served as Gilead’s General Counsel.
“Corcept’s FDA-approved medication Korlym and the drug candidates it is developing have the potential to benefit millions of patients,” said Mr. Alton. “I look forward to contributing to the advancement of such a rich commercial and clinical program.”
About Corcept Therapeutics
We are a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. We have discovered a large portfolio of proprietary compounds, including relacorilant, exicorilant and miricorilant, that selectively modulate the effects of cortisol but not progesterone. We own extensive United States and foreign intellectual property covering the composition of our selective cortisol modulators and the use of cortisol modulators, including mifepristone, to treat a variety of serious disorders.
For more information: https://www.corcept.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.